Biogen discontinues Alzheimer’s medication Aduhelm - CNN
WEBJan 31, 2024 — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
WEBJan 31, 2024 — Biogen’s decision to abandon its ownership rights to Aduhelm closes out a yearslong saga that generated outrage and eroded trust in the regulatory process for bringing new medicines to market.
Biogen’s Decision to Discontinue Alzheimer’s Drug | alz.org
WEBCHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of Alzheimer’s treatments; a new era that started with the Food and Drug Administration (FDA) accelerated approval of …
Biogen to stop selling controversial Alzheimer's drug Aduhelm - NBC News
WEBJan 31, 2024 — Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday...
Biogen to shut down controversial Alzheimer's drug Aduhelm
WEBJan 31, 2024 — Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration.
Biogen Quits Controversial Alzheimer’s Drug Aduhelm - WSJ
WEBJan 31, 2024 — Biogen is pulling the plug on its ill-fated Alzheimer’s disease drug Aduhelm. The company said it is ending the development and sale of Aduhelm and terminating a postmarketing study aimed at...
Biogen ends sales of Alzheimer's drug Aduhelm - USA TODAY
WEBJan 31, 2024 — Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a...
Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter
WEBJan 31 (Reuters) - Biogen (BIIB.O) will end a post-approval study of Alzheimer's treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs...
Biogen drops Alzheimer's drug Aduhelm to focus on Leqembi, …
WEBJan 31, 2024 — Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the...
Biogen will stop selling its controversial Alzheimer’s drug Aduhelm
WEBJan 31, 2024 — Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said...